NCI 5611: PHASE II STUDY OF BEVACIZUMAB (RHUMAB-VEGF) IN HEPATOCELLULAR CANCER

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。目的是：(1)确定贝伐单抗对不能切除的肝细胞癌(没有门静脉主干或转移的肿瘤)的疗效和安全性；(2)收集贝伐单抗治疗前后的动态增强MRI所确定的肿瘤血管血流动力学的信息；(3)收集也有助于肝细胞癌发病的血管内皮生长因子和相关细胞因子的循环水平的信息，以及在抑制血管内皮生长因子的背景下这些水平的潜在变化；以及(4)收集关于肝功能和肝炎病毒活性的信息以及在抑制血管内皮生长因子的背景下的潜在变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims are: (1) to determine efficacy and safety of bevacizumab in patients with unresectable hepatocellular cancer (without tumor invasion of main portal vein or metastasis); (2) to collect information on tumor vascular perfusion kinetics, as determined by dynamic gadolinium-enhanced MRI, before and following bevacizumab therapy; (3) to collect information circulating levels of VEGF and related cytokines which also contribute to HCC pathogenesis and on potential alterations of these levels in the setting of VEGF-inhibition; and (4) to collect information on hepatic function and hepatitis viral activity in cirrhosis and upon potential alterations in the setting of VEGF inhibit